Is Liquidia Corp (LQDA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.9% / 30% | 5.6% / 30% | 0.1% / 30% | 54.69% / 5% | ✗ NOT HALAL |
| DJIM | 3.9% / 33% | 5.6% / 33% | 0.1% / 33% | 54.69% / 5% | ✗ NOT HALAL |
| MSCI | 53.1% / 33% | 76.6% / 33% | 1.2% / 33% | 54.69% / 5% | ✗ NOT HALAL |
| S&P | 3.9% / 33% | 5.6% / 33% | 0.1% / 33% | 54.69% / 5% | ✗ NOT HALAL |
| FTSE | 53.1% / 33% | 76.6% / 33% | 1.2% / 50% | 54.69% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 91.6% | |
| Operating Margin | 21.5% | |
| Net Margin | -43.5% | |
| Return on Equity (ROE) | -111.1% | |
| Return on Assets (ROA) | -11.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$36M |
| Free Cash Flow | -$42M |
| Total Debt | $198M |
| Debt-to-Equity | 442.3 |
| Current Ratio | 2.0 |
| Total Assets | $328M |
Price & Trading
| Last Close | $36.77 |
| 50-Day MA | $37.66 |
| 200-Day MA | $27.88 |
| Avg Volume | 1.9M |
| Beta | 0.6 |
|
52-Week Range
$11.26
| |
About Liquidia Corp (LQDA)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Liquidia Corp (LQDA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Liquidia Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Liquidia Corp's debt ratio?
Liquidia Corp's debt ratio is 3.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 53.1%.
What are Liquidia Corp's key financial metrics?
Liquidia Corp has a market capitalization of $3.1B, and revenue of $158M. The company maintains a gross margin of 91.6% and a net margin of -43.5%. Return on equity stands at -111.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.